Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704583 | 0.94 | TLR7 (0.44) | TLR7KCNH2CYP2D6CYP3A4CYP2C8 | |
| SCHEMBL29970597 | 0.91 | TLR7 (0.42) | TLR7KCNH2CYP2D6CYP3A4CYP2C8 | |
| SCHEMBL23704425 | 0.90 | TLR7 (0.43) | TLR7KCNH2CYP2D6CYP3A4APP | |
| SCHEMBL29970738 | 0.86 | TLR7 (0.42) | TLR7KCNH2CYP2D6CYP3A4CYP2C8 | |
| SCHEMBL23703527 | 0.86 | TLR7 (0.44) | TLR7KCNH2CYP2D6CYP3A4 | |
| SCHEMBL29971148 | 0.85 | TLR7 (0.42) | TLR7KCNH2CYP2D6CYP3A4 | |
| SCHEMBL23718889 | 0.85 | TLR7 (0.42) | TLR7KCNH2CYP2D6CYP3A4 | |
| SCHEMBL23704586 | 0.84 | TLR7 (0.43) | TLR7KCNH2CYP2D6CYP3A4APP | |
| SCHEMBL29970945 | 0.82 | TLR7 (0.40) | TLR7KCNH2CYP2D6CYP3A4 | |
| SCHEMBL23718972 | 0.81 | TLR7 (0.44) | TLR7KCNH2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131192-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
| EP-4097105-A1 | 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021154664-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131192-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | TLR7 1/4885KCNH2 3706/4885CYP2D6 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.